株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

Vical Incorporated:製品パイプライン分析

Vical Incorporated - Product Pipeline Review - 2015

発行 Global Markets Direct 商品コード 224604
出版日 ページ情報 英文 34 Pages
即納可能
価格
本日の銀行送金レート: 1USD=115.27円で換算しております。

2016年12月31日まで 年末キャンペーン割引: Global Markets Direct社発行レポート
ご注意: ショッピングカートでは適用されませんので、割引価格についてはお問い合わせください

Back to Top
Vical Incorporated:製品パイプライン分析 Vical Incorporated - Product Pipeline Review - 2015
出版日: 2015年07月15日 ページ情報: 英文 34 Pages
概要

Vical Incorporatedは、生命を脅かす疾患の予防および治療を目的とした、DNAデリバリー技術をベースとするバイオ医薬品の研究開発を行うバイオ医薬品企業です。

当レポートでは、Vical Incorporatedにおける治療薬開発パイプラインの現況と各開発段階の比較分析、薬剤標的、作用機序、投与経路、分子タイプ別の治療薬の評価、最新の企業ニュースや発表、後期段階および中止されたプロジェクトに関する情報などを提供しています。

Vical Incorporatedの基本情報

  • Vical Incorporatedの概要
  • 主要情報
  • 企業情報

Vical Incorporated:R&Dの概要

  • 主な治療範囲

Vical Incorporated:パイプラインのレビュー

  • 開発段階別のパイプライン製品
  • 単剤製品
  • パートナー製品
    • パートナー製品/併用療法モダリティ
  • アウトライセンス製品
    • アウトライセンス製品/併用療法モダリティ

Vical Incorporated:パイプライン製品の概況

  • 治験段階にあるパイプライン製品
    • 第I相にある製品/併用療法モダリティ
  • 初期段階にあるパイプライン製品
    • IND/CTA 出願製品/併用療法モダリティ
    • 前臨床段階にある製品/併用療法モダリティ

Vical Incorporated:薬剤プロファイル

  • VCLHB-01
  • VCLHM-01
  • CyMVectin
  • ASP-2397
  • 麻疹向けワクチン

Vical Incorporated:パイプライン分析

  • 標的別
  • 投与経路別
  • 分子タイプ別
  • 作用機序別

Vical Incorporated:最近のパイプライン動向

Vical Incorporated:休止中のプロジェクト

Vical Incorporated:開発が中止されたパイプライン製品

  • 開発が中止されたパイプライン製品のプロファイル
    • HIV Vaccine

Vical Incorporated:企業発表

Vical Incorporated:本社と子会社の所在地

付録

図表

このページに掲載されている内容は最新版と異なる場合があります。詳細はお問い合わせください。

目次
Product Code: GMDHC07301CDB

Summary

Global Markets Direct's, 'Vical Incorporated - Product Pipeline Review - 2015', provides an overview of the Vical Incorporated's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Vical Incorporated's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Vical Incorporated including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Vical Incorporated's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Vical Incorporated's pipeline products

Reasons to buy

  • Evaluate Vical Incorporated's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Vical Incorporated in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Vical Incorporated's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Vical Incorporated and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Vical Incorporated
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Vical Incorporated and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Vical Incorporated Snapshot
    • Vical Incorporated Overview
    • Key Information
    • Key Facts
  • Vical Incorporated - Research and Development Overview
    • Key Therapeutic Areas
  • Vical Incorporated - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Partnered Products
      • Partnered Products/Combination Treatment Modalities
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Vical Incorporated - Pipeline Products Glance
    • Vical Incorporated - Clinical Stage Pipeline Products
      • Phase I Products/Combination Treatment Modalities
    • Vical Incorporated - Early Stage Pipeline Products
      • IND/CTA Filed Products/Combination Treatment Modalities
      • Preclinical Products/Combination Treatment Modalities
  • Vical Incorporated - Drug Profiles
    • VCLHB-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • VCLHM-01
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • CyMVectin
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ASP-2397
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • measles (bivalent) vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Vical Incorporated - Pipeline Analysis
    • Vical Incorporated - Pipeline Products by Target
    • Vical Incorporated - Pipeline Products by Route of Administration
    • Vical Incorporated - Pipeline Products by Molecule Type
  • Vical Incorporated - Recent Pipeline Updates
  • Vical Incorporated - Dormant Projects
  • Vical Incorporated - Discontinued Pipeline Products
    • Discontinued Pipeline Product Profiles
      • HIV Vaccine
  • Vical Incorporated - Company Statement
  • Vical Incorporated - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Vical Incorporated, Key Information
  • Vical Incorporated, Key Facts
  • Vical Incorporated - Pipeline by Indication, 2015
  • Vical Incorporated - Pipeline by Stage of Development, 2015
  • Vical Incorporated - Monotherapy Products in Pipeline, 2015
  • Vical Incorporated - Partnered Products in Pipeline, 2015
  • Vical Incorporated - Partnered Products/ Combination Treatment Modalities, 2015
  • Vical Incorporated - Out-Licensed Products in Pipeline, 2015
  • Vical Incorporated - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Vical Incorporated - Phase I, 2015
  • Vical Incorporated - IND/CTA Filed, 2015
  • Vical Incorporated - Preclinical, 2015
  • Vical Incorporated - Pipeline by Target, 2015
  • Vical Incorporated - Pipeline by Route of Administration, 2015
  • Vical Incorporated - Pipeline by Molecule Type, 2015
  • Vical Incorporated - Recent Pipeline Updates, 2015
  • Vical Incorporated - Dormant Developmental Projects,2015
  • Vical Incorporated - Discontinued Pipeline Products, 2015

List of Figures

  • Vical Incorporated - Pipeline by Top 10 Indication, 2015
  • Vical Incorporated - Pipeline by Stage of Development, 2015
  • Vical Incorporated - Monotherapy Products in Pipeline, 2015
  • Vical Incorporated - Partnered Products in Pipeline, 2015
  • Vical Incorporated - Pipeline by Top 10 Target, 2015
  • Vical Incorporated - Pipeline by Top 10 Molecule Type, 2015
Back to Top